Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label ""Tolcapone tablets are contraindicated in patients with liver disease, in patients who were withdrawn from Tolcapone tablets because of evidence of Tolcapone tablets-induced hepatocellular injury or who have demonstrated hypersensitivity to the drug or its ingredients. Tolcapone tablets is also contraindicated in patients with a history of nontraumatic rhabdomyolysis or hyperpyrexia and confusion possibly related to medication (see PRECAUTIONS: Events Reported With Dopaminergic Therapy"" assertion.
- association label ""CONTRAINDICATIONS Diclofenac Sodium Delayed-Release Tablets should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS, ANAPHYLACTOID REACTIONS, and PRECAUTIONS, PREEXISTING ASTHMA). Diclofenac Sodium Delayed-Release Tablets, USP are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see WARNINGS]."" assertion.
- association label ""1. Current or past history of thrombophlebitis, thromboembolic disorders, or cerebral apoplexy. 2. Liver dysfunction or disease. 3. Known or suspected malignancy of breast or genital organs. 4. Undiagnosed vaginal bleeding. 5. Missed abortion. 6. Known sensitivity to progesterone injection."" assertion.
- association label "Anuria. Hypersensitivity to any component of this product or to other sulfonamide-derived drugs." assertion.
- association label "Calcitriol Oral Solution should not be given to patients with hypercalcemia or evidence of vitamin D toxicity. Use of Calcitriol Oral Solution in patients with known hypersensitivity to Calcitriol Oral Solution (or drugs of the same class) or any of the inactive ingredients is contraindicated." assertion.
- association label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" assertion.
- context label "Children and adolescents (6-17 years)" assertion.
- context label "Children and adolescents (mean age 15.3 years)" assertion.
- association label "Stigler et al. [10] evaluated the effectiveness and tolerability of paliperidone for irritability in ASD. In this 8-week, prospective, open-label study, 21 (84%) of 25 subjects with ASD (mean age, 15.3 years) were considered responders to paliperidone (mean dosage, 7.1 mg/day), based on Clinical Global Impression (CGI)- Improvement and Aberrant Behaviour Checklist-Irritability sub- scale.v" assertion.
- association label "Yamamuro et al. [13] have reported on 3 CAP cases with TS treated with paliperidone. In 2 cases, TS symptoms were remark- ably improved by switching from haloperidol to paliperidone ex- tended release, and in another case, paliperidone-extended release showed significant efficacy in treating TS symptoms as the first-line drug." assertion.
- context label "Children and adolescents" assertion.
- MONDO_0007661 label "Tourette syndrome" assertion.
- association label "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality dis- order, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved." assertion.
- context label "Adolescents (15-17)" assertion.
- context label "Children and adolescents" assertion.
- association label "Clozapine has a more significant impact for the treatment of positive psychotic symptoms as compared to negative symptoms and has been shown to be effective for aggression, suicidal behaviors, obsessive–compulsive disorder, and autism spectrum disorder." assertion.
- context label "Adults" assertion.
- association label "Lamotrigine has been long used as an anti-epileptic, mood stabilizer, to treat bipolar disorder in adults and off label as an antidepressant." assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- context label "Adults" assertion.
- association label "Only a few pharmacological treatments are available for treating alcohol use disorders (AUDs). Disulfiram, naltrexone and acamprosate are Food and Drug Administration (FDA)-approved and nalmefene is EMA-approved in European Union. Off-label medications, such as baclofen, gabapentin, ondansetron and topiramate are medications commonly prescribed for the treatment of AUD." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Citicoline was well tolerated but did not reduce alcohol consump- tion compared with placebo as measured by the time line follow back-method. The authors conclude that although citicoline has shown promise on many fields, it did not prove beneficial in treating AUD in these patients" assertion.
- association label "In a study published by Wilcox et al. [19], the alpha- 1 adrenergic receptor antagonist prazosin did not differ from placebo in reducing alcohol consump- tion in 36 participants." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "The purpose of this review is to summarize the current evidence of the off-label use of intravenous (IV) olanzapine and discuss its risks versus benefits for the management of agitation." assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- association label "Psychosis is broadly defined as a disengagement from reality. It describes syndromes that impair both thought content and thought process. Psychosis negatively impacts an individual's quality of life, in addition to the families caring for them. Psychosis with different types of hallucinations and delusions occurs in the context of delirium. Neuropsychiatric symptoms (NPS) are almost universal in the course of common neurodegenerative disorders (NDD) like Alzheimer's disease (AD) or Parkinson's disease (PD). In this paper, the authors took an effort to characterize AD and PD psychosis with a special focus on the most diagnostically reliable features. Quetiapine (see supplement) is also commonly used in (off-label) for NPS in AD." assertion.
- context label "Adults" assertion.
- association label "Psychosis is broadly defined as a disengagement from reality. It describes syndromes that impair both thought content and thought process. Psychosis negatively impacts an individual's quality of life, in addition to the families caring for them. Psychosis with different types of hallucinations and delusions occurs in the context of delirium. Neuropsychiatric symptoms (NPS) are almost universal in the course of common neurodegenerative disorders (NDD) like Alzheimer's disease (AD) or Parkinson's disease (PD). In this paper, the authors took an effort to characterize AD and PD psychosis with a special focus on the most diagnostically reliable features. Quetiapine (see supplement) is also commonly used in (off-label) for NPS in AD." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Among those drugs, modafinil (MOD) and its ( R)-enantiomer (R-MOD) have been used off-label as therapies for psychostimulant use disorders, but they have shown limited effectiveness in clinical trials psychostimulant use disorder" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- MONDO_0005414 label "Treatment-refractory schizophrenia" assertion.
- association label "Clinical trial data for mood disorders as well as other psychiatric disorders, including borderline personality disorder, schizophrenia, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder, and panic disorder, will be discussed" assertion.
- context label "Adults" assertion.
- association label "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Insomnia—c/w trazodone at night”" assertion.
- association label "Clinician's annotation: “Depression: stable: continue Paxil and trazodone for sleep”" assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Will try an antidepressant to see if it helps to improve interest in activities. The history is suggestive of depression”" assertion.
- HP_0012154 label "anhedonia" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Back pain improved with addition of nortriptyline”" assertion.
- HP_0003418 label "back pain" assertion.
- association label "Clinician's annotation: “Menopausal syndrome—given smoking and hyperlipidemia, we will try nonhormonal options. Rx prozac”" assertion.
- context label "Adults" assertion.
- NCIT_C34814 label "menopause" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation “bmi 37.5, discussed wt loss surgery and drugs, on anafranil (Clomipramine)”" assertion.
- HP_0001824 label "Weight loss" assertion.
- context label "adults" assertion.
- association label "Guidelines recommend the use of neuromodulators in patients with functional dyspepsia not responding to proton pump inhibitors (PPIs) and prokinetics; however, there is a lack of data from randomised controlled trials supporting their use." assertion.
- association label "Ketamine is not yet approved by regulatory agencies, but is widely used off‐label by private so‐called ketamine clinics." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- MONDO_0002491 label "substance abuse" assertion.
- MONDO_0002491 label "substance abuse" assertion.
- MONDO_0002491 label "substance abuse" assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- association label "Two other sedating antidepressants, mirtazapine and trimipramine, are commonly used off-label for the treatment of ID without clear recommendations by any of the guidelines." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults.(...) Several off-label drugs, especially lisinopril, candesartan, and amitriptyline also have good evidence of benefit." assertion.
- context label "adults" assertion.
- association label "This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults.(...) Several off-label drugs, especially lisinopril, candesartan, and amitriptyline also have good evidence of benefit." assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- context label "adults" assertion.
- association label ""Sulfasalazine tablets are contraindicated in: Patients with intestinal or urinary obstruction, Patients with porphyria as sulfonamides have been reported to precipitate an acute attack, Patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates."" assertion.
- association label ""Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension, or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.1 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.2 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients [See Dosage and Administration section"" assertion.
- association label ""Moexipril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Do not coadminister aliskiren with moexipril hydrochloride in patients with diabetes (see PRECAUTION Drug Interactions"" assertion.
- association label ""Aminocaproic Acid Tablets should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering Aminocaproic Acid Tablets. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic Acid Tablets must not be used in the presence of DIC without concomitant heparin."" assertion.
- association label ""Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. Perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. [see Drug Interactions (7.8) ] [see Warnings and Precautions (5.1) Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema. ( 4 5.1 Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes ( 4 7.8 Do not take a neprilysin inhibitor with perindopril erbumine tablets ( 4 Do not administer perindopril erbumine tablets within 36 hours of switching to or from sacubitril/valsartan ( 4"" assertion.
- association label ""Parasympathomimetics are contraindicated where miosis is undesirable such as acute iritis or pupillary block glaucoma. This product is also contraindicated in persons hypersensitive to one or more of the components of this preparation."" assertion.
- association label ""Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines. Agitated states. Patients with a history of drug abuse. During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result)."" assertion.
- association label "Leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin B12. A hematologic remission may occur while neurologic manifestations continue to progress." assertion.